Mouse Tumor Biology Database (MTB)
MTB Home   Help
Search for Help
in these sections
Search Forms
Pathology Images
Search MTB Using Human Genes
Gene Expression Data Sets

Additional Resources
new PDX Like Me
PDX Finder
PDX Model Search
Faceted Tumor Search
Dynamic Tumor Frequency Grid
Other Cancer Websites
Lymphoma Pathology

Mouse Genome Informatics
The Jackson Laboratory
Citing These Resources
Warranty Disclaimer
& Copyright Notice

Send Questions and
Comments to User Support.

Last Database Update
MTB 3.0
HelpHelp and Documentation Reference Detail  
Title: Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.
Authors: Stevenson WS; Hyland CD; Zhang JG; Morgan PO; Willson TA; Gill A; Hilton AA; Viney EM; Bahlo M; Masters SL; Hennebry S; Richardson SJ; Nicola NA; Metcalf D; Hilton DJ; Roberts AW; Alexander WS
Journal: Proc Natl Acad Sci U S A
Volume: 107
Issue: 38
Year: 2010
Pages: 16625-30
Abstract: With the notable exception of humans, uric acid is degraded to (S)-allantoin in a biochemical pathway catalyzed by urate oxidase, 5-hydroxyisourate (HIU) hydrolase, and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase in most vertebrate species. A point mutation in the gene encoding mouse HIU hydrolase, Urah, that perturbed uric acid metabolism within the liver was discovered during a mutagenesis screen in mice. The predicted substitution of cysteine for tyrosine in a conserved helical region of the mutant-encoded HIU hydrolase resulted in undetectable protein expression. Mice homozygous for this mutation developed elevated platelet counts secondary to excess thrombopoietin production and hepatomegaly. The majority of homozygous mutant mice also developed hepatocellular carcinoma, and tumor development was accelerated by exposure to radiation. The development of hepatomegaly and liver tumors in mice lacking Urah suggests that uric acid metabolites may be toxic and that urate oxidase activity without HIU hydrolase function may affect liver growth and transformation. The absence of HIU hydrolase in humans predicts slowed metabolism of HIU after clinical administration of exogenous urate oxidase in conditions of uric acid-related pathology. The data suggest that prolonged urate oxidase therapy should be combined with careful assessment of toxicity associated with extrahepatic production of uric acid metabolites.
in MTB
Tumor Records (8)
Strains (2)
J:164423  Mouse Genome Informatics
20823251  National Library of Medicine/PubMed